Acquisition of the Drug Evolocumab [140 Mg/1 Ml; Inj Solution; Pen] for ULSCB

This tender involves the acquisition of the drug Evolocumab, which is specified as a solution for injection in a pen format, with a concentration of 140 mg per 1 ml. The procurement is intended for the ULSCB (Unidade Local de Saúde do Cávado e do Ave), a local health unit in Portugal. The tender aims to ensure the availability of this essential medication for patients requiring treatment for specific medical conditions, such as hyperlipidemia. Key requirements for bidders may include compliance with pharmaceutical regulations, quality assurance standards, and the ability to deliver the product within stipulated timelines. Interested suppliers should also demonstrate their capacity to provide the medication in the specified format and concentration, ensuring that all necessary documentation and certifications are in place. This acquisition is crucial for maintaining the health services provided by ULSCB and improving patient outcomes in the region. The tender process will follow standard public procurement procedures, ensuring transparency and competitiveness in the selection of suppliers.

This is a supplies contract in the health and medical services and trade and industry sectors, with a focus on Pharmaceuticals. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 14,501.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.